Overview

A Study of CDX-0159 in Patients With Prurigo Nodularis

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to explore the safety, clinical effect, pharmacodynamics, and pharmacokinetics of CDX-0159 in patients with Prurigo Nodularis.
Phase:
Phase 1
Details
Lead Sponsor:
Celldex Therapeutics